血清WFA + -M2BP水平肝纤维化的早期阶段的评估慢性乙肝病毒感

StephenW

Serum WFA+-M2BP levels for evaluation of early stages of liver fibrosis in patients with chronic hepatitis B virus infection

    Xia Zou1,2,4,†, Ming-Yu Zhu1,†, De-Min Yu1, Wei Li2, Dong-Hua Zhang1, Fei-Jie Lu2, Gong Qi-Ming1, Feng Liu2, Jiang Jie-Hong1, Min-Hua Zheng4, Atsushi Kuno3, Hisashi Narimatsu3, Yan Zhang2,6,* andXin-Xin Zhang1,5,*

DOI: 10.1111/liv.13188

This article is protected by copyright. All rights reserved.


Cover image for Vol. 36 Issue 7
Liver International

Accepted Article (Accepted, unedited articles published online and citable. The final edited and typeset version of record will appear in future.)
Article has an altmetric score of 2

    1    Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
    2    Ministry of Education Key Laboratory of Systems Biomedicine, Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai, China
    3    Research Center for Medical Glycoscience, National Institute of Advanced Industrial Science and Technology (AIST), Tsukuba, Ibaraki, Japan
    4    Department of Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
    5    Translational Medicine Research Center, Ruijin Hospital North, Shanghai Jiao Tong University School of Medicine, Shanghai, China
    6    Collaborative Innovation Center of Systems Biomedicine, Shanghai, China

    †    These authors contributed equally to this work

* Corresponding Authors:
Yan Zhang, Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University,800 Dong Chuan Road, Minhang, Shanghai 200240, China
Tel.: +86-21-34206778; E-mail: [email protected]
Xinxin Zhang, Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
Tel.: +86-21-64370045; E-mail: [email protected]

    This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/liv.13188


Keywords:

    Wisteria floribunda agglutinin;Mac-2 binding protein;liver fibrosis;chronic hepatitis B

Abstract
Background & Aims

Accurately evaluation of liver fibrosis is crucial for predicting progression of chronic hepatitis B virus (HBV) infection. We assessed the utility of a novel fibrosis glycobiomarker Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA+-M2BP) for evaluating liver fibrosis and disease progression in patients with chronic HBV infection.
Methods

We enrolled 774 patients with chronic HBV infection, with or without fibrosis, diagnosed by liver biopsy/FibroScan. Patients who underwent liver biopsy (n=297) were divided into training (n=221) and validation (n=76) groups. Serum WFA+-M2BP values were measured and compared with FIB-4 index, aspartate aminotransferase(AST) to platelet ratio (APRI), and AST to alanine aminotransferase ratio (AAR) using receiver operating characteristic (ROC) analysis.
Results

Serum WFA+-M2BP levels increased significantly with fibrosis progression (P<0.0001). Area under the ROC curve of WFA+-M2BP for diagnosing significant fibrosis was higher than that of FIB-4 (P=0.198), APRI (P=0.017), and AAR (P<0.001), with sensitivity and specificity in the training set of 60.5% and 79.8%; and validation set of 59.5% and 82.1%, respectively. Serum WFA+-M2BP levels were significantly correlated with FibroScan values (P<0.0001), and improved the accuracy of FibroScan in assessing significant fibrosis. Changes in WFA+-M2BP levels were parallel with those in FibroScan values during nucleot(s)ide analogues therapy in patients with chronic HBV infection.
Conclusions

WFA+-M2BP is an accurate serum indicator for assessing early stages of liver fibrosis, and may monitor regression of fibrosis during the treatment of chronic HBV infection. WFA+-M2BP provides a simple and reliable alternative or complementary method to liver biopsy and FibroScan.

This article is protected by copyright. All rights reserved.

StephenW

血清WFA + -M2BP水平肝纤维化的早期阶段的评估慢性乙肝病毒感染

    夏Zou1,2,4，†，铭宇Zhu1，†，德珉宇1，魏Li2的，冬华Zhang1，费杰LU2，龚齐明1，冯刘备，江洁红1，民华Zheng4，淳Kuno3，尚志Narimatsu3，严Zhang2,6，* andXin鑫Zhang1,5，*

DOI：10.1111 / liv.13188

本文由版权保护。版权所有。


封面图片的卷。 36问题7
肝国际

接受第（接受，未经编辑的文章在网上和可引用的公布。最终的编辑和记录的排版本将出现在未来。）
制品具有为2的altmetric得分

    传染病科1，医学院瑞金医院，上海，中国的上海交通大学医学院
    系统生物医学的上海中心系统生物医学研究院上海交通大学上海，中国教育部重点实验室，2个教育部
    3研究中心医疗Glycoscience，先进工业科学和技术研究院（AIST），筑波，茨城县，日本
    外科4系，医学院瑞金医院，上海，中国的上海交通大学医学院
    5转化医学研究中心，瑞金医院北，中医药的上海交通大学医学院，上海，中国
    系统生物医学研究院，上海，中国6个协同创新中心

    †这些作者也同样促成了这一工作

*通讯作者：
张燕，上海中心系统生物医学研究院，上海交通大学，东川路800号，上海市闵行区，上海200240，中国
电话：+ 86-21-34206778;电子信箱：[email protected]
张欣欣，感染科，医学院瑞金医院上海交通大学医学院，上海200025，中国
电话：+ 86-21-64370045;电子信箱：[email protected]

    这篇文章已被接受发表，并接受全面的同行评审，但经过审稿，排版，分页和校对过程中，这可能会导致这个版本和记录的版本之间的差异一直没有。请引用这篇文章的DOI：10.1111 / liv.13188


关键词：

    多花紫藤凝集素的Mac-2结合蛋白，肝纤维化，慢性乙型肝炎

抽象
背景和目的

准确肝纤维化的评价是用于预测慢性乙型肝炎病毒（HBV）感染的进展是至关重要的。我们评估一个新的纤维化glycobiomarker多花紫藤凝集素阳性的Mac-2结合蛋白（WFA + -M2BP）的应用程序，用于治疗慢性HBV感染评估肝纤维化和疾病进展。
方法

我们招收774例慢性HBV感染，有无纤维化，诊断为肝活检/肝纤维。谁接受肝活检（N = 297）患者被分为训练（N = 221）和验证（N = 76）组。测定血清WFA + -M2BP值并用FIB-4索引，天冬氨酸转氨酶（AST）血小板比率（APRI），和AST使用受试者工作特征（ROC）分析丙氨酸转氨酶比（AAR）相比较。
结果

血清WFA + -M2BP水平与纤维化进展（P <0.0001）显著上升。 WFA + -M2BP的诊断显著纤维化的ROC曲线下面积比FIB-4（P = 0.198），APRI（P = 0.017），和AAR（P <0.001）的更高，在训练组的灵敏度和特异性的60.5％和79.8％;和验证分别设定为59.5％和82.1％。血清WFA + -M2BP水平与肝纤维值（P <0.0001）分别显著相关，改善肝纤维的准确性评估显著纤维化。在WFA + -M2BP水平变化与nucleot在那些在肝纤维平行值（S）类似物治疗慢性HBV感染的治疗。
结论

WFA + -M2BP是用于评估肝纤维化的早期阶段的准确血清指示器，和慢性HBV感染的治疗过程中可以监测纤维化消退。 WFA + -M2BP提供了一种简单且可靠的替代或补充方法肝活检和肝纤维。

本文由版权保护。版权所有。